Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
2.555
+0.055 (2.20%)
Mar 4, 2026, 3:23 PM EST - Market open
Eledon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Eledon Pharmaceuticals stock have an average target of 8.50, with a low estimate of 8.00 and a high estimate of 9.00. The average target predicts an increase of 232.68% from the current stock price of 2.56.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 18, 2025.
Analyst Ratings
The average analyst rating for Eledon Pharmaceuticals stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +213.11% | Nov 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +252.25% | Sep 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +252.25% | Jun 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +526.22% | Nov 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +526.22% | Jun 4, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.69
from -0.75
EPS Next Year
-0.90
from -0.69
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.62 | -0.76 | ||||
| Avg | -0.69 | -0.90 | ||||
| Low | -0.84 | -1.28 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.